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Abstract
Aim Whether a prostate cancer diagnosis induces
response shift has not been established so far. Therefore,
we assessed response shift in men who were diagnosed
with localized prostate cancer.
Patients and methods Out of 3,892 men who completed a
questionnaire before screening, 82 were subsequently
diagnosed with prostate cancer. Response shift was asses-
sed in 52 (response 63%) by the then-test (EuroQol self-
rating of health, Short-Form 36 mental health and vitality)
and a novel method: rating of vignettes relating to side
effects of prostate cancer treatment (urinary, bowel and
erectile dysfunction). Three then-tests were conducted: two
referencing pre-diagnosis (measured pre- and post-treat-
ment), and one referencing pre-treatment (measured post-
treatment).
Results Then-test scores of pre-diagnosis health were
signiﬁcantly higher than original scores, indicating a more
positive judgement in retrospect. Then-test scores of
pre-treatment health were lower than original scores.
Especially the vignette on erectile dysfunction was rated
less bad after diagnosis versus before (P\0.001, moderate
effect size).
Conclusions We found evidence for response shift in men
who were diagnosed with prostate cancer. Men evaluated
urinary, bowel, and erectile dysfunction as less bad after
they had become patients who can expect to experience
these side effects. The rating of vignettes is a promising
additional technique to assess response shift.
Keywords Patient-reported outcome  Prostate cancer 
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Introduction
Response shift, deﬁned as an adaptation to changing health
[1], is a beneﬁcial process for patients because it can help
in adapting to a new situation. However, it may complicate
the correct interpretation of change in health-related quality
of life (QoL) scores over time in intervention studies, and
therefore needs to be understood. Response shift refers to a
change in the meaning of QoL over time [2] and can result
from a change in one’s internal standards of measurement
(i.e. recalibration), a change in the importance attributed to
the domains constituting QoL (i.e. change in values or
reprioritization), or a change in the deﬁnition of the con-
cept of QoL (i.e. reconceptualization) [3, 4]. These three
forms of response shift are illustrated in the following
example. Imagine a woman X. When asked to rate her QoL
she thought of her (50-h a week) job, her partner and
playing volleyball with friends, and rated her QoL as very
good. Unfortunately she fell ill. For some months she was
not able to work. Her partner and relatives supported her a
great deal, which she appreciated enormously. Gradually
she recovered and started working again for 20 h a week,
but was no longer able to play volleyball. She rated her
new QoL again as very good, but this time the main aspects
of her QoL consisted of her partner, her family and work.
Her ratings did not change, i.e. twice ‘very good’, but in
fact three forms of response shift had occurred. ‘Work’
changed from a 50-h a week job to 20 h a week (recali-
bration), her partner became more important
(reprioritization), and her concept of QoL has changed: no
more sports, but relatives instead (reconceptualization).
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induced by a prostate cancer diagnosis. Schwartz and
colleagues systematically addressed the state-of-the-art in
the assessment and interpretation of response shift [5].
In a meta-analysis, following Cochrane guidelines, the
magnitude and clinical relevance of response shifts across
19 longitudinal studies were evaluated. Most studies
addressed global QoL and speciﬁc QoL domains such as
fatigue, well-being, and pain, usually by conducting the
then-test. Effect sizes, deﬁned as the mean difference
between tests divided by the standard deviation (SD) of
the ﬁrst assessment, were computed by the authors. These
were generally small according to Cohen’s criteria [6],
with the largest effect sizes found for fatigue, followed by
global QoL, physical role limitation, physical well-being,
and pain. Effect sizes varied in direction, which compli-
cated their interpretation. Schwartz et al. concluded with
recommendations for future response shift publications,
such as explaining the meaning of the study results in
terms of recalibration, reprioritization, and reconceptual-
ization [5].
Response shift is more likely to occur when an intense
and pervasive change in health is experienced [7]. A cancer
diagnosis may have a large impact on a person’s experi-
enced health. Our group previously described the process
of being diagnosed with prostate cancer through a screen-
ing process consisting of a Prostate Speciﬁc Antigen (PSA)
test and, if indicated, a biopsy. Typically, localized prostate
cancer diagnosed through screening is not associated with
any physical symptoms. Men’s mental health and the val-
uation of their own health decreased signiﬁcantly after they
received their diagnosis, and we concluded that being
diagnosed with prostate cancer was a deeply felt change in
health [8]. We started the present study because we
expected that a prostate cancer diagnosis induces response
shift. We hypothesized that the pre-diagnosis health state
would be rated more positively in retrospect (i.e. if asses-
sed after diagnosis) than at the reference point itself
(i.e. pre-diagnosis).
Collecting data on QoL before a cancer diagnosis is
usually not feasible, since it is unknown who will develop
cancer and when, so that the inclusion of a very large
cohort would be required. However, the context of the
European Randomized study for Screening on Prostate
Cancer (ERSPC) [9] enabled us to include a cohort of
men shortly before they were screened and subsequently
diagnosed. We aimed at assessing the magnitude and
direction of response shift effects after diagnosis and
again after primary treatment. We employed two meth-
ods: the common then-test and a novel approach including
rating of vignettes related to side effects of prostate
cancer treatment (urinary, bowel, and erectile
dysfunction).
Patients and methods
Ethics approval and informed consent
The Ethics Committee of the Erasmus MC approved the
research protocol. All participants gave additional written
informed consent to be interviewed for the study.
Parent study
Inclusion of the ERSPC participants was initiated in 1994
among all male inhabitants of the Rotterdam region aged
between 55 and 74 years. The only exclusion criterion was
a previous prostate cancer diagnosis. Details on study
recruitment for the ERSPC have been reported earlier [9].
Respondents
Randomly selected participants from the parent study were
approached. All men who were due for the second
(n = 2,798) or third screening round (n = 2,024) between
January 2003 and May 2004 were sent a short question-
naire on health (see below) by mail. Men who were
diagnosed through the screening process were interviewed
twice by one of the authors (IK); one month post-diagnosis
(but before treatment) and again 7 months post-diagnosis.
Assessing response shift
To assess the magnitude and direction of response shift
effects two methods were used: the then-test, and vignettes
(a novel method in response shift research). For the
resulting study scheme, see Fig. 1.
(1). The then-test is a retrospective evaluation of an
earlier assessment (retrospective pre-test-post-test
design). At post-test respondents are asked to
remember how they were doing at the reference
point and to retrospectively rate their level of
functioning or QoL at that time. The then-test was
originally developed to measure recalibration. The
method assumes that respondents will use their post-
test internal standards when providing a re-evalua-
tion or ‘then-test’ rating of their health at the
reference point [5]. The comparison between the
then-test and the post-test is thus assumed not to be
confounded by recalibration and can be considered as
an indication of true change [2]. The comparison of
the mean pre-test, which is the assessment that was
completed at the reference point, and then-test scores
would reﬂect an estimate of the magnitude and
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123direction of response shift [2]. Because respondents
in our study were included before diagnosis, they
could provide then-test scores relating to their health
before diagnosis and to their health between diagno-
sis and treatment. Before completing the then-test,
respondents were explicitly reminded about the
period the then-test was referring to: e.g. the time
when the respondents had not yet been diagnosed
with prostate cancer and were unaware of having
prostate cancer. Respondents were then asked to
re-assess their health at that time. Three then-tests
were conducted: two referencing pre-diagnosis
health (measured at 1 month post-diagnosis and
7 months post-diagnosis) and one referencing
1-month post diagnosis health (measured at 7-months
post-diagnosis), see Figs. 2, 3, 4. The respondents
completed generic QoL measures, i.e. the Short-
Form 36 (SF-36) mental health and vitality, and the
EQ-5D VAS for self-rated health, as a pre-test, post-
test and then-test. The SF-36 consists of eight scales
on physical and mental domains of health. We used
the scales on mental health (ﬁve items on being
nervous, down, peaceful, depressed and happy) and
vitality (four items on being full of life, having a lot
of energy, being worn out and tired). Higher scores
(0–100) indicate better mental health and vitality
[10]. The EuroQol (EQ) 5D valuation of own health
is a visual analog scale on current overall health,
anchored at the lower end (0) by ‘worst imaginable
health state’ and at the upper end (100) by ‘best
imaginable health state’ [11].
(2). As a novel method to assess response shift we used
vignettes that each described a health state relating
to side effects of therapy for localized prostate
cancer, i.e. urinary, bowel or erectile dysfunction.
The vignettes contained items of the EQ-5D self-
classiﬁer complemented with items on dysfunction,
for instance, ‘Mr. A has no problems in walking
about, has no problems washing or dressing himself,
experiences urinary leakage daily, has no pain or
discomfort, is not anxious or depressed’. Respon-
dents were asked to indicate how good or bad they
evaluated these health states on visual analog scales
anchored at the lower end (0) by ‘very bad’ and at
the upper end (10) by ‘very good’. We used the
vignettes to explore reprioritization. We hypothe-
sized that men would value the health states as less
detrimental after diagnosis than before. After diag-
nosis they knew they might experience these
dysfunctions themselves in the context of prostate
cancer treatment.
Additionally, information on respondents’ age and on the
Gleason score (a clinical criterion for histological grading
of the aggressiveness of the tumour) were obtained through
the screening ofﬁce.
Statistical analysis
Procedures concerning imputation of missing responses in
the SF-36 items were conducted according to the guide-
lines of the SF-36 Health Survey Manual [12]. Differences
between assessments were tested with paired-samples
t-tests. P-values £ 0.05 were considered statistically sig-
niﬁcant. The type I error rate, i.e. the ratio of signiﬁcant
ﬁndings to the number of comparisons, was calculated. To
assess the magnitude of the differences between the
assessments we used Cohen’s effect sizes, deﬁned as the
mean difference between tests divided by the SD of the ﬁrst
assessment, and interpreted as follows: 0.2\d\0.5
indicates a small, 0.5 £ d\0.8 a moderate, and d ‡ 0.8 a
large effect size [6].
The minimal important difference (MID), which is the
smallest change in a patient-reported outcome that is per-
ceived by patients as beneﬁcial or that would result in a
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123change of treatment, was operationalized as a difference of
at least half a SD [13].
Non-response bias was analysed by testing differences
between the respondents and the non-respondents with
unpaired t-tests.
Results
Out of the 3,892 men who completed the initial question-
naire before screening on prostate cancer, 82 were
subsequently diagnosed. Of these, 52 (response 63%)
consented to participate in two additional telephone inter-
views at 1 and at 7 months post-diagnosis. All 52
respondents participated in the ﬁrst interview, which took
place before treatment had been initiated. Due to personal
circumstances one respondent later refused the second
telephone interview. Average age at screening was
67.3 years (SD 4.4), ranging from 60 to 74 years. The
Gleason score was favourable in 42 of the 52 patients, i.e.
below seven (Table 1). In all respondents but one, treatment
had been initiated at 7 months post-diagnosis, i.e. radical
prostatectomy (n = 25), brachytherapy (n = 12), active
surveillance (n = 10), external radiotherapy (n = 3), or
hormonal treatment (n = 1), see Table 1.
Original scores, i.e. scores relating to the respondents’
health at the time of the assessment and interviews, and
then-test scores relating to the two reference points are
given in Table 2. For example, ‘85.2’ in the upper right
corner of Table 2 reﬂects the ‘EQ valuation of own health’
score of the then-test measured at 7 months post-diagnosis
referencing 2 months pre-diagnosis. Mental and self-rated
health scores worsened signiﬁcantly from 2 months pre-
ceding diagnosis to 1 month post-diagnosis. The average
mental health score, for instance, was 83.2 at 2 months pre-
diagnosis, and 75.8 at 1-month post-diagnosis; a decrease
of 7.4 that exceeds the MID. At 7 months post-diagnosis
mental and own health scores had increased again, but not
to their original level.
2 months 
pre-diagnosis
0
75
80
85
90
95
100
Original scores
Then test measured at 1 month post-diagnosis
Then test measured at 7 months post-diagnosis
1 month
post-diagnosis
7 months
post-diagnosis
EuroQol VAS valuation of own health
True
change
Observed
change
Response
shift
Fig. 2 Original and then-test scores of the EuroQol valuation of own
health by prostate cancer patients (n = 52). If we measure only EQ-
VAS preceding diagnosis and at 1-month post-diagnosis, the differ-
ence between these scores is regarded the ‘observed change’.
However, if the retrospective pre-diagnosis assessment provides a
more valid comparison with the post-diagnosis assessment, the ‘true
change’ is reﬂected by the difference between the retrospective pre-
diagnosis assessment and the post-diagnosis assessment. The differ-
ence between the pre-diagnosis assessment and the retrospective pre-
diagnosis assessment provides an indication of the size and direction
of the ‘response shift’ induced by the diagnosis. Similar explanations
are valid for the other data points in the ﬁgure
2 months 
pre-diagnosis
0
75
80
85
90
95
100
Original scores
Then test measured at 1 month post-diagnosis
Then test measured at 7 months post-diagnosis
1 month 
post- diagnosis
7 months 
post-diagnosis
SF-36 Mental Health
Observed 
change  
True
change 
Response
Shift 
Fig. 3 Original and then-test scores of the SF-36 mental health by
prostate cancer patients (n = 52). ‘Observed change’, ‘True change’
and ‘Response shift’ refer to the differences in SF-36 mental health
scores between the assessment at 2 months before diagnosis and post-
and then-test at 1 month after diagnosis (for further explanation, see
caption at Fig. 2.)
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pre-diagnosis
0
75
80
85
90
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Then test measured at 1 month post-diagnosis
Then test measured at 7 months post-diagnosis
1 month 
post-diagnosis
7 months 
post-diagnosis
SF-36 Vitality
True 
change Observed
change
Response
shift
Fig. 4 Original and then-test scores of the SF-36 vitality by prostate
cancer patients (n = 52). ‘Observed change’, ‘True change’ and
‘Response shift’ refer to the differences in SF-36 vitality scores
between the assessment at 2 months before diagnosis and post- and
thentestthen-test at 1 month after diagnosis (for further explanation,
see caption at Fig. 2.)
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123Original scores of pre-diagnosis health were lower,
indicating worse health than on the then-test scores. For
example, the original pre-diagnosis mental health score
was 83.2 on average, but the then-test score measured at
1 month post-diagnosis was 84.5, indicating a more posi-
tive judgement of pre-diagnosis mental health in retrospect.
Original scores of health between diagnosis and treatment,
on the other hand, were higher, indicating better health than
on the then-test scores. The original vitality score, for
instance, was 74.7 at 1 month post-diagnosis, but the then-
test score measured at 7 months post-diagnosis was 72.6.
This means that vitality between diagnosis and treatment
was judged worse when measured in retrospect than when
measured at the reference point itself. Original and then-
test scores are presented in Figs. 2–4, including estimates
of the response shift effects, i.e. the difference between
mean pre-test and then-test scores, and estimates of ‘true’
change, i.e. the difference between the mean post-test and
then-test scores.
Effect sizes of the differences between then-test and
original scores were small (Table 2).
The vignettes describing urinary, bowel and erectile
dysfunction states were rated signiﬁcantly higher (i.e.
better) by respondents at 1 month post-diagnosis than at
2 months pre-diagnosis (P-values 0.038, 0.011, and
\0.001, respectively). The valuation of erectile dysfunc-
tion showed the largest increase; i.e. from 5.3 to 6.7 on a
0–10 scale, with a moderate effect size of 0.57 (Table 3).
This implies that respondents considered especially erectile
dysfunction less detrimental after diagnosis with prostate
cancer than before diagnosis. The differences between pre-
and post-diagnosis valuations of the vignettes exceeded the
MID in 4 out of 6 cases (Table 3).
The results of the then-test were signiﬁcant in 4 out of 9
comparisons, the results of the vignettes in 5 out of 6. The
overall type I error rate, which is the ratio of signiﬁcant
ﬁndings to the number of comparisons, was 0.6 (9 out
of 15).
Table 1 Gleason scores and
treatment modality of the
respondents (n = 52)
Gleason score\7 n = 42 Gleason score ‡ 7 n = 10 Total n =5 2
Radical prostatectomy 18 7 25
External radiotherapy 1 2 3
Brachytherapy 13 13
Active surveillance 9 9
Hormonal treatment 1 1
No treatment choice yet 1 1
Table 2 Mean health scores (standard deviation) of the respondents (n = 52) before and after diagnosis, original and thentests scores
Referring to
Original scores
(n = 52) P-value*
Thentests
1 month
post-diagnosis
(n = 52)
P-value:
thentest vs.
original
Effect size:
thentest vs
original
7 months
post-diagnosis
(n = 51)
P-value:
thentest vs.
original
Effect size:
thentest vs.
original
2 months pre-diagnosis
EuroQol own health 80.2 (11.7) 83.2 (9.0) 0.058 –0.26 85.2 (7.6) 0.002
a –0.43
SF-36 mental health 83.2 (11.6) 84.5 (11.0) 0.304 –0.10 83.2 (10.9) 1.00 0.01
SF-36 vitality 75.3 (15.6) 79.6 (12.0) 0.008 –0.28 79.4 (12.4) 0.046 –0.26
1 month post-diagnosis, before initiation of treatment
EuroQol own health 74.5 (15.1) 0.010 74.1 (14.5) 0.618 0.03
SF-36 mental health 75.8 (16.8) 0.001
a 72.8 (18.3) 0.042 0.17
SF-36 vitality 74.7 (14.2) 0.771 72.6 (13.7) 0.111 0.15
7 months post-diagnosis, after intiation of treatment in 80% of respondents
EuroQol own health 77.6 (13.7) 0.196
SF-36 mental health 80.4 (13.8) 0.066
SF-36 vitality 73.1 (17.7) 0.213
*P-value of difference with previous original score (P £ 0.05 are considered signiﬁcant)
a Change exceeds the minimal important difference (operationalised as ½ standard deviation)
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123Non-response analysis
The baseline average age in men who were diagnosed with
prostate cancer but did not respond to the questionnaire
(n = 30) was 66.7 (SD 4.3, range 59–73) years. Respon-
dents and non-respondents did not differ signiﬁcantly in
age or other health measures (data not shown).
Discussion
Men diagnosed with prostate cancer evaluated their pre-
diagnosis health in retrospect as better than at the reference
point itself. Post-diagnosis–pre-treatment health was rated
worse in retrospect than at the reference point. This
suggests that ‘true’ changes in health between the ﬁrst
assessment before diagnosis and the second one at 1 month
post-diagnosis were larger than the original scores dis-
closed, and that response shifts were induced by ﬁrst, the
diagnosis, and second, subsequent treatment. The sizes of
the response shifts induced by the diagnosis were larger
than those induced by the treatment. The negligible to
small effect sizes indicated that only some recalibration
occurred. The directions of the effect sizes were inter-
pretable and consistent with our hypotheses.
Additionally, men evaluated vignettes relating to side
effects of prostate cancer treatment as less detrimental after
they were diagnosed than before diagnosis. We interpreted
this change as a reprioritization of respondents who
became aware after being diagnosed with prostate cancer
that they were at risk of experiencing these health states
themselves as a consequence of being treated for prostate
cancer. In this new context dysfunctional health states were
evaluated as less bad than before. The effect sizes were
moderate for erectile dysfunction and small in the two
other ones, indicating that reprioritization also occurred.
The directions of the effect sizes were interpretable and
consistent with our hypotheses.
The overall type I error rate was 0.6, which indicated
that the statistical signiﬁcance is very unlikely to be caused
by chance. This is an additional indication that our ﬁndings
reﬂect real differences. We conclude that the results of the
then-tests and the ratings of the vignettes both indicate the
presence of a response shift and adaptation of the patients
to their new situation.
In the meta-analysis of Schwartz et al., the largest effect
sizes on response shift (although still small) were found for
the dimensions global QoL and fatigue [5]. These dimen-
sions, represented in our study by EQ-5D on own health
and the SF-36 vitality scale respectively, also resulted in
small effect sizes.
An important criticism of the then-test approach is its
susceptibility to recall bias. Respondents are supposed to
be able to remember their previous health at the reference
point, which is extremely difﬁcult in case of a chronic
disease with no obvious trend towards better or worse
health [14]. However, in a study on response shift in cancer
patients undergoing various forms of treatment, there was
evidence that recall bias was absent [2]. We assume that in
the case of a deeply felt change in health (such as being
diagnosed with cancer or the initiation of cancer therapy)
recall will not cause memory difﬁculties for most respon-
dents. Therefore, in our study we expect that recall bias did
not have a major inﬂuence on the results.
The then-test results in a retrospective judgement that
subsequently is used to construct ‘real change’ since the
reference point. This approach assumes that the informa-
tion that was acquired after the original judgment was
made leads to more accurate estimates of QoL than the
original judgment itself. This assumption is, however, not
always true; for example in the case that the newly
acquired information is not correct [14].
The valuation of disease-speciﬁc vignettes (the second
method used to assess response shift) has to our knowledge
not been described before. It resulted in a moderate effect
size considering the vignette on erectile dysfunction. The
directions of the effect sizes were consistent with our
hypotheses. Our results showed that response shift can be
studied by using vignettes. We consider the valuation of
vignettes as a useful addition to the already available col-
lection of tools to assess response shift. Apart from this
theoretical value, the results of the vignettes may also have
implications for clinical practice. In case of a diagnosis of
localized prostate cancer several treatment options are
Table 3 Average valuation by VAS (SD) of prostate cancer speciﬁc vignettes, scale 0-10, P-values £ 0.05 were considered signiﬁcant
Health state
description
Pre-diagnosis
(n = 52)
1 month
post-diagnosis
(n = 52)
P-value
pre-diagnosis
vs. 1 month
post-diagnosis
Effect size
pre-diagnosis
vs. 1 month
post-diagnosis
7 months post
diagnosis
(n = 51)
P-value
pre-diagnosis
vs. 7 months
post-diagnosis
Effect size
pre-diagnosis
vs. 7 months
post-diagnosis
Daily urinary leakage 5.6 (2.1) 6.3 (1.5)
a 0.038 –0.32 5.9 (1.5) 0.348 –0.14
Daily bowel cramps 5.3 (2.0) 6.0 (1.6) 0.011 –0.41 6.2 (1.4)
a 0.012 –0.39
Serious erectile dysfunction 5.3 (2.2) 6.7 (1.8)
a \0.001 –0.57 6.5 (1.8)
a 0.005 –0.47
a change compared to previous score exceeds minimal important difference
1632 Qual Life Res (2007) 16:1627–1634
123available. Since there is no consensus about which of these
treatments has the best outcome in terms of survival and
QoL, considerations of patient preferences regarding mode
of treatment and side effects are an essential element in
shared decision making on the choice of therapy. To elicit a
patient’s preferences and his individual trade-offs between
beneﬁts and side effects of various modes of treatment,
vignettes can be useful [15].
However, our study showed that patient preferences may
changeinthecourseofthediagnosticandtreatmentprocess,
which illustrates how difﬁcult it is for a patient to imagine
theconsequencesofaninterventioninadvance.Thisﬁnding
conﬁrms the point made by Cowen et al. to recommend the
use of individual utilities (‘‘actually prefer’’) instead of
population’s utilities (‘‘should prefer’’) to optimise the
choice of treatment for patients with prostate cancer [16].
We recommend further investigation of the vignettes
method. The fact that being diagnosed with prostate cancer
was found to induce response shift may be seen as an indi-
cation thatmen regardaprostate cancerdiagnosisasamajor
life event, and is additional evidence for earlier ﬁndings [8].
In another study, men with metastic or locally advanced
prostate cancer completed assessments on prostate symp-
toms shortly after diagnosis, and 3 and 6 months thereafter.
The second and third assessments included then-tests. The
presence of a response shift was suggested in patients and
their spouses [17, 18]. The authors remarked that retro-
spective and prospective assessments cannot be used
interchangeably.
Lepore and Eton tested two conceptual models of
response shift among men newly diagnosed with prostate
cancer to explain the frequently observed lack of associa-
tion between health problems and QoL in cancer patients.
No support was found for the suppressor model, according
to which health change leads to response shift, which in
turn leads to a change in QoL. Some evidence was found
for the buffering model, according to which response shift
effects moderate the negative association between health
problems and QoL. Two aspects of response shift, recali-
bration and reprioritization, were assessed by then-tests and
a measure of primary life goal changes, respectively. They
were found to moderate the relation between negative
changes in physical health and changes in QoL [19].
Indications of response shift were also found in an
earlier study on men treated for localized prostate cancer.
Men stated, for instance, that they accepted the side effects
of treatment because ‘If they hadn’t intervened, that
operation, maybe I wouldn’t be here anymore’ [20].
The present study has several strengths and limitations.
The study design is one of its strengths; the unique context
of the ERSPC enabled the inclusion of respondents before
they (or anyone else) were aware that they had prostate
cancer, which is usually unfeasible. To our knowledge this
is the ﬁrst study to measure response shift in men who were
diagnosed with cancer. An additional strength is the com-
pliance of the respondents; 51 of the 52 respondents
completed the 7-month assessment.
For the then-test we selected measures that are consid-
ered subjective (i.e. SF-36 mental health and vitality, and
EQ-5D of own health) but no objective items, which can be
considered a drawback of the study. Furthermore, we
acknowledge that offering questionnaires in two different
modes (self-administered questionnaires before diagnosis
vs. telephone interviews afterwards) may have been less
than optimal. This design was chosen based on practical
considerations, because assessments by telephone in 3,892
screen participants was not feasible, and self-administered
questionnaires at 1 month after diagnosis undesirable since
we wanted these assessments to be completed before the
initiation of treatment. The unavailability of information on
marital status and education is also a drawback. Another
potential limitation of our study is that the interval between
the initiation of treatment and the assessment at 7-months
post-diagnosis was not the same for all respondents; it is
possible that response shift may vary according to the
length of time that elapsed since treatment. However,
information on this interval had been of limited use. The
most common therapies for localized prostate cancer
nowadays are surgery, radiotherapy, and active surveil-
lance. These therapies differ greatly (by nature) in duration,
the onset of side effects and their course over time.
It may be that particular groups may be more prone to
response shift than others, e.g. depending on age or prog-
nosis. We plan to address this issue further, preferably in a
larger sample than used in the current study.
Conclusions
Using two complementary techniques we found that a
diagnosis of prostate cancer induces response shift. From a
methodology point of view, the vignette-method needs to
be explored further.
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